[HTML] mdpi.com

[HTML][HTML] Predictive and prognostic factors in HCC patients treated with sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - Medicina, 2019 - mdpi.com
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …
被引用次数：73 相关文章

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - 2019 - preprints.org
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.

O Brunetti, A Gnoni, A Licchetta, V Longo… - Medicina (Kaunas …, 2019 - europepmc.org
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - MEDICINA, 2019 - ricerca.uniba.it
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …
[PDF] semanticscholar.org

[PDF][PDF] Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo… - …, 2019 - pdfs.semanticscholar.org
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …
[HTML] nih.gov

[HTML][HTML] Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - Medicina, 2019 - ncbi.nlm.nih.gov
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …

Predictive and prognostic factors in HCC patients treated with sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - MEDICINA, 2019 - iris.unisr.it
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …
[PDF] archive.org

[PDF][PDF] Predictive and prognostic factors in HCC patients treated with Sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - 2019 - scholar.archive.org
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …

Predictive and prognostic factors in HCC patients treated with sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - MEDICINA, 2019 - iris.unimore.it
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese… - Medicina, 2019 - cir.nii.ac.jp
抄録< jats: p> Sorafenib is an oral kinase inhibitor that enhances survival in patients affected
by advanced hepatocellular carcinoma (HCC). According to the results of two registrative …